Board approves Q1 results, new CFO, pharma subsidiary acquisition

Management Changes View source PDF Explain this filing

JLHL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.1%Reaction day

₹330.00

prior close

₹325.00

announcement price

After-mkt

timing

Nifty Microcap 250market+1.3%-3.5% vs market

Hospital peers, median of 25sector+0.5%-2.7% vs sector

On the reaction day the stock moved 3.5 pts less than Nifty Microcap 250 and 2.7 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-3.2

10m

-2.3

15m

-2.1

30m

-2.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.1+1.3-3.5+0.5-2.7

Next day

-2.1+1.8-3.9+0.2-2.4

-2.1+3.1-5.2-0.1-2.1

-2.5+3.5-5.9+0.4-2.9

-3.0+3.5-6.5+1.7-4.7

-2.4+3.4-5.9+2.9-5.3

-8.1+3.6-11.8-0.4-7.7

15d

-6.8+4.9-11.7-2.6-4.3

-11.6+4.4-16.0-2.7-8.9

-23.0+2.9-25.9-9.1-13.9

—————

UpDownMarket · Nifty Microcap 250Sector · Hospital peers, median of 25Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q1 FY27 (June 2026): Standalone revenue about Rs 312 cr (vs Rs 212 cr YoY), net profit about Rs 47 cr. Consolidated revenue about Rs 388 cr, net profit about Rs 62 cr, EPS Rs 5.72. Board appointed Harshad Purani as CFO. Subsidiary JHPPL acquired 100% of Sulcus Private for Rs 3.78 cr (related party deal with promoters) to set up an IV fluids and pharma manufacturing facility in Ujjain, with Rs 35-40 cr further investment planned.

Likely market impact

Strong YoY revenue and profit growth; new CFO appointed; strategic expansion into pharma manufacturing through subsidiary.